US Bancorp DE lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 2.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 239,233 shares of the company's stock after buying an additional 6,814 shares during the quarter. US Bancorp DE's holdings in AstraZeneca were worth $15,675,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new stake in shares of AstraZeneca in the third quarter worth approximately $28,000. Albion Financial Group UT raised its stake in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company's stock valued at $40,000 after purchasing an additional 248 shares in the last quarter. Groupama Asset Managment boosted its holdings in shares of AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company's stock worth $42,000 after purchasing an additional 101,225 shares during the period. Ashton Thomas Securities LLC purchased a new position in shares of AstraZeneca during the third quarter valued at approximately $45,000. Finally, Versant Capital Management Inc lifted its holdings in AstraZeneca by 2,618.5% during the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company's stock valued at $48,000 after buying an additional 707 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the stock. UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. Morgan Stanley started coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating for the company. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a "sell" rating to a "hold" rating in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $89.75.
Read Our Latest Analysis on AZN
AstraZeneca Stock Up 1.0 %
Shares of AZN stock traded up $0.76 during trading hours on Wednesday, reaching $78.01. 3,310,180 shares of the stock were exchanged, compared to its average volume of 5,618,479. The business's fifty day moving average is $70.16 and its two-hundred day moving average is $72.81. The firm has a market capitalization of $241.92 billion, a P/E ratio of 34.54, a P/E/G ratio of 1.42 and a beta of 0.46. AstraZeneca PLC has a 12-month low of $62.75 and a 12-month high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts' consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. As a group, research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.
AstraZeneca Increases Dividend
The business also recently announced a semi-annual dividend, which will be paid on Monday, March 24th. Investors of record on Friday, February 21st will be given a $1.03 dividend. This represents a dividend yield of 2%. This is an increase from AstraZeneca's previous semi-annual dividend of $0.49. The ex-dividend date of this dividend is Friday, February 21st. AstraZeneca's dividend payout ratio (DPR) is 91.15%.
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
